Posting of Annual Report & Notice of AGM - Total Voting Rights
15 5월 2024 - 4:57PM
May 15, 2024
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
Posting of Annual Report & Notice of
AGM
Total Voting Rights
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a
clinical stage biopharmaceutical company developing a pipeline of
innovative products for the treatment of diseases with unmet
medical needs, announces that its Notice of Annual General Meeting
(“AGM”) was posted to shareholders yesterday, along with the Annual
Report for the year ended 31 December 2023. The document is also
available on the “Investors” section of the Company’s website at
www.biodexapharma.com/investors/financial-reports-and-presentations/#financial-reports
The Company will hold the 2024 AGM at its
offices at 12.00 noon BST at 1 Caspian Point, Caspian Way, Cardiff,
CF10 4DQ on 13 June 2024. Further details on how to vote by proxy
are set out in the Notice of AGM.
Total Voting Rights
The Company's issued share capital comprises
2,238,225,722 Ordinary Shares each with voting rights. The Company
does not hold any shares in treasury. This figure of 2,238,225,722
may be used by shareholders in the Company as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
share capital of the Company. Each of the Company’s American
Depositary Shares comprises 400 Ordinary Shares.
For more information, please contact:
Biodexa
Pharmaceuticals PLC |
Tel: +44 (0)29
20480180 |
www.biodexapharma.com |
|
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ:
BDRX) is a clinical stage biopharmaceutical company developing a
pipeline of innovative products for the treatment of diseases with
unmet medical needs. The Company’s lead development programs
include eRapa, under development for Familial Adenomatous Polyposis
and Non Muscle Invasive Blader Cancer: tolimidone, under
development as a for the treatment of type 1 diabetes; and MTX110,
which is being studied in aggressive rare/orphan brain cancer
indications.
eRapa is a proprietary oral tablet formulation
of rapamycin, also known as sirolimus. Rapamycin is an mTOR
(mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to
have a significant role in the signalling pathway that regulates
cellular metabolism, growth and proliferation and is activated
during tumorgenesis.
Tolimidone is an orally delivered, potent and
selective inhibitor of Lyn kinase. Lyn is a member of the Src
family of protein tyrosine kinases, which is mainly expressed in
hematopoietic cells, in neural tissues, liver, and adipose tissue.
Tolimidone demonstrates glycemic control via insulin sensitization
in animal models of diabetes and has the potential to become a
first in class blood glucose modulating agent.
MTX110 is a solubilised formulation of the
histone deacetylase (HDAC) inhibitor, panobinostat. This
proprietary formulation enables delivery of the product via
convection-enhanced delivery (CED) at chemotherapeutic doses
directly to the site of the tumor, by-passing the blood-brain
barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug
delivery technologies focused on improving the bio-delivery and
bio-distribution of medicines. Biodexa’s headquarters and R&D
facility is in Cardiff, UK. For more information visit
www.biodexapharma.com.
Biodexa Pharmaceuticals (NASDAQ:BDRX)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Biodexa Pharmaceuticals (NASDAQ:BDRX)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024